BACKGROUND: This study had two goals (1) to evaluate changes in neuropsychological performance among cognitively normal individuals that might precede the onset of clinical symptoms, and (2) to examine the impact of Apolipoprotein E (ApoE) genotype on these changes. METHODS: Longitudinal neuropsychological, clinical assessments and consensus diagnoses were completed prospectively in 268 cognitively normal individuals. The mean duration of follow-up was 9.2 years (+/- 3.3). 208 participants remained normal and 60 developed cognitive decline, consistent with a diagnosis of MCI or dementia. Cox regression analyses were completed, for both baseline scores and rate of change in scores, in relation to time to onset of clinical symptoms. Analyses were completed both with and without ApoE-4 status included. Interactions with ApoE-4 status were also examined. RESULTS: Lower baseline test scores, as well as greater rate of change in test scores, were associated with time to onset of clinical symptoms (p<0.001). The mean time from baseline to onset of clinical symptoms was 6.15 (+/- 3.4) years. The presence of an ApoE-4 allele doubled the risk of progression. The rate of change in two of the test scores was significantly different in ApoE-4 carriers vs. non-carriers. CONCLUSIONS: Cognitive performance declines prior to the onset of clinical symptoms that are a harbinger of a diagnosis of MCI. Cognitive changes in normal individuals who will subsequently decline may be observed at least 6.5 years prior to symptom onset. In addition, the risk of decline is doubled among individuals with an ApoE-4 allele.
BACKGROUND: This study had two goals (1) to evaluate changes in neuropsychological performance among cognitively normal individuals that might precede the onset of clinical symptoms, and (2) to examine the impact of Apolipoprotein E (ApoE) genotype on these changes. METHODS: Longitudinal neuropsychological, clinical assessments and consensus diagnoses were completed prospectively in 268 cognitively normal individuals. The mean duration of follow-up was 9.2 years (+/- 3.3). 208 participants remained normal and 60 developed cognitive decline, consistent with a diagnosis of MCI or dementia. Cox regression analyses were completed, for both baseline scores and rate of change in scores, in relation to time to onset of clinical symptoms. Analyses were completed both with and without ApoE-4 status included. Interactions with ApoE-4 status were also examined. RESULTS: Lower baseline test scores, as well as greater rate of change in test scores, were associated with time to onset of clinical symptoms (p<0.001). The mean time from baseline to onset of clinical symptoms was 6.15 (+/- 3.4) years. The presence of an ApoE-4 allele doubled the risk of progression. The rate of change in two of the test scores was significantly different in ApoE-4 carriers vs. non-carriers. CONCLUSIONS: Cognitive performance declines prior to the onset of clinical symptoms that are a harbinger of a diagnosis of MCI. Cognitive changes in normal individuals who will subsequently decline may be observed at least 6.5 years prior to symptom onset. In addition, the risk of decline is doubled among individuals with an ApoE-4 allele.
Authors: C H Kawas; M M Corrada; R Brookmeyer; A Morrison; S M Resnick; A B Zonderman; D Arenberg Journal: Neurology Date: 2003-04-08 Impact factor: 9.910
Authors: Richard J Caselli; Amylou C Dueck; David Osborne; Marwan N Sabbagh; Donald J Connor; Geoffrey L Ahern; Leslie C Baxter; Steven Z Rapcsak; Jiong Shi; Bryan K Woodruff; Dona E C Locke; Charlene Hoffman Snyder; Gene E Alexander; Rosa Rademakers; Eric M Reiman Journal: N Engl J Med Date: 2009-07-16 Impact factor: 91.245
Authors: James A Levy; Judy Bergeson; Karen Putnam; Virginia Rosen; Robert Cohen; Francois Lalonde; Nadeem Mirza; Gary Linker; Trey Sunderland Journal: J Int Neuropsychol Soc Date: 2004-05 Impact factor: 2.892
Authors: R J Caselli; E M Reiman; D Osborne; J G Hentz; L C Baxter; J L Hernandez; G G Alexander Journal: Neurology Date: 2004-06-08 Impact factor: 9.910
Authors: Hélène Amieva; Mélanie Le Goff; Xavier Millet; Jean Marc Orgogozo; Karine Pérès; Pascale Barberger-Gateau; Hélène Jacqmin-Gadda; Jean François Dartigues Journal: Ann Neurol Date: 2008-11 Impact factor: 10.422
Authors: L A Farrer; L A Cupples; J L Haines; B Hyman; W A Kukull; R Mayeux; R H Myers; M A Pericak-Vance; N Risch; C M van Duijn Journal: JAMA Date: 1997 Oct 22-29 Impact factor: 56.272
Authors: Susan M Resnick; Murat Bilgel; Abhay Moghekar; Yang An; Qing Cai; Mei-Cheng Wang; Madhav Thambisetty; Jerry L Prince; Yun Zhou; Anja Soldan; Dean F Wong; Richard J O'Brien; Luigi Ferrucci; Marilyn S Albert Journal: Neurobiol Aging Date: 2015-04-04 Impact factor: 4.673
Authors: V R Varma; S Varma; Y An; T J Hohman; S Seddighi; R Casanova; A Beri; E B Dammer; N T Seyfried; O Pletnikova; A Moghekar; M R Wilson; J J Lah; R J O'Brien; A I Levey; J C Troncoso; M S Albert; M Thambisetty Journal: Mol Psychiatry Date: 2016-11-22 Impact factor: 15.992
Authors: Anja Soldan; Corinne Pettigrew; Anne M Fagan; Suzanne E Schindler; Abhay Moghekar; Christopher Fowler; Qiao-Xin Li; Steven J Collins; Cynthia Carlsson; Sanjay Asthana; Colin L Masters; Sterling Johnson; John C Morris; Marilyn Albert; Alden L Gross Journal: Neurology Date: 2019-03-06 Impact factor: 9.910
Authors: Lindsay R Clark; Rebecca L Koscik; Christopher R Nicholas; Ozioma C Okonkwo; Corinne D Engelman; Lisa C Bratzke; Kirk J Hogan; Kimberly D Mueller; Barbara B Bendlin; Cynthia M Carlsson; Sanjay Asthana; Mark A Sager; Bruce P Hermann; Sterling C Johnson Journal: Arch Clin Neuropsychol Date: 2016-11-22 Impact factor: 2.813